Expanding Clinical Pipelines, Contract Manufacturing Adoption, and Automation-Led Process Innovation Fuel Robust Market Growth Globally.Austin, United States, Feb. 27, 2026 (GLOBE NEWSWIRE) -- ...
What is the current status of cell therapies today? It's an exciting time to be in cell therapy manufacturing and commercialization, particularly in the oncology space. This year alone, we've seen the ...
PHC Corporation’s Biomedical Division (Head Office: Chiyoda-ku, Tokyo; President: Nobuaki Nakamura; hereinafter “PHCbi”), a global provider of laboratory sample storage and cell cultivation solutions ...
Europe’s battery startups keep hitting the same wall: expensive power, slower scaling, heavy capex, and relentless price competition from Asian giants backed by industrial policy. Without competitive ...
Adoptive therapies based on CAR/TCR T cells—that is, T cells with an engineered chimeric antigen receptor (CAR) or a T-cell receptor (TCR)—have shown promise for a range of cancers, offering hope to ...
Automated cell therapy manufacturing pioneer Cellares has hit a key milestone, gaining a current Good Manufacturing Practice (cGMP) stamp of approval for its Cell Shuttle factory-in-a-box, which is ...
Not all patients respond well to chimeric antigen receptor (CAR) T cell therapies, which reprogram a patient’s own immune cells to recognize and attack cancer. A way to optimize these treatments is to ...
TOPCon Cells? BANGALORE, India, Feb. 23, 2026 /PRNewswire/ -- The global market for N-TOPCon Cells was valued at USD 10020 Million in the year 2024 and is projected to reach a revised size of USD ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results